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PROTEIN BIOMARKERS OF MULTIPLE SCLEROSIS; STUDIES OF 
CEREBROSPINAL FLUIDS FROM CLINICALLY DIFFERENT SUBTYPES 
OF MS PATIENTS 
SUMMARY 
Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central 
nervous system (CNS) which widely appears in the adults. It shows heterogenous 
lesions in the clinical and pathological phenotype which limits the quality of life 
standarts. In the pathogenesis of MS, the destruction of oligodentrocytes, neurons 
and axons play important role. In this regard, the destruction of myelin tissue in the 
white and grey matter causes irreversible function defects and a progressive disorder 
type. It is possibly autoimmune disorder which affected by both environmental and 
genetic factors. Because MS is a complex neuroimmune disorder, treatment of it is 
against the symtoms of the disease. On the other hand, diagnosis of the disease is 
also depend on the presence of symptoms and thus it is needed to have some 
parameters that facilitate and make easier the diagnosis of MS. 
Recent proteomic studies directed to find protein biomarkers in the body fluids of 
MS patients, to facilitate the diagnosis of the disorder. Those studies showed that 
there are some proteins, found in the cerebrospinal fluid and the serum of the patient, 
that show difference in the course and the subtype of MS. Also, the level and the 
kind of proteins differ, when you compare the control groups protein levels with the 
different subtypes of the MS. 
In this study, the basic aim is, to investigate the protein biomarkers which are chosen 
by the previous literature findings and can help th diagnosis of MS by comparing the 
level of them with the control groups and the different MS subtypes. In this regard, 
20 clinic isolated syndrome patient, 20 relapsing-remitting MS, 20 primary 
progressive MS, 20 secondary progressive MS and 20 control groups which have 
different neurologic disorder and should have lumber punction because of that 
disease (compatible with the patient group as age and sex), planned to be collected 
by the İstanbul University, Cerrahpasa Medicine Faculty, Neuroimmunology and the 
Demyelination Service. In the CSF samples and serums, Myelin Basic Protein 
(MBP), myelin oligodentrosite glycoprotein (MOG), Tau protein, Glial Fibrillary 
Acidic protein (GFAP) and neurofilament light chain (NF-L) proteins were 
investigated with the Western Blot technique. The findings were analyzed under 
“ImageJ Analyses” programme, to compare the levels of proteins in different groups. 
At the end, the evaluation of these proteins as a biomarker in the diagnosis and the 
course of the disease were discussed. 
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At the end of the study, it is observed that, four of five proteins showed statistically 
significant results between both RRMS (n=31) and CIS (n=25) groups to be a 
candidate biomarker of MS. When the protein levels were compared in RRMS group 
with control group (n=12), it is observed that, concentration of Tau protein %53 
(p=0.0004), GFAP 67% (p=0.0034), NF – L 67% (p=0.0015) and MOG 76% 
(p<0.0001) proteins was increased. The same proteins in CIS groups were compared 
with control group and it is observed that; concentration Tau protein %46 
(p=0.0029), GFAP 67% (p=0.0036), NF – L 68% (p=0.0037) and MOG 77% 
(p<0.0001) was increased. For the MBP, results did not show any stattistically 
significant data. Our preliminary results, indicates that, Tau, GFAP, NF – L and 
MOG proteins can be functional in the diagnosis and prognosis of MS. Further 
studies will continue with increasing the number of samples and serum samples of 
the same patients will be evaluated in order to make correlation between serum and 
CSF samples. 
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KLİNİK OLARAK FARKLI MULTİPL SKLEROZ ALT GRUBU 
HASTALARININ BEYİN OMURİLİK SIVILARINDA MS 
BİYOBELİRTEÇLERİ ÇALIŞMASI 
ÖZET 
Multiple skleroz (MS) genellikle genç erişkinlerde görülen, alevlenme ve 
düzelmelerle seyreden, merkezi sinir sistemini birçok lokalizasyonda etkileyen, 
genetik ve çevresel etmenlerin karmaşık etkileşmeleri sonucu oluştuğu varsayılan, 
olasılıkla otoimmün, inflamatuar demyelinizasyonun yanında akson kaybı ve 
oligodentrositlerin yıkımı ile seyreden kronik bir hastalıktır. Merkezi Sinir 
Sisteminin (MSS) ak maddesini çeşitli lokalizasyonda etkileyen kronik ve yaşam 
kalitesini sınırlayan bir doğası vardır. Hastalığın immünopatolojisinde ve genetiğinde 
birçok etkenler vardır. MS kompleks bir hastalık olması dolayısı ile hastalığın 
tedavisi semptomları gidermeye yönelik olup, hastalığın tanısının koyulması da 
semptomların görülmesine bağlı olarak gerçekleştirilebilmektedir. Bu nedenle 
hastalığın tanısını kolaylaştırıcı parametrelere ihtiyaç duyulmaktadır. 
Son yıllarda yapılan proteomik çalışmalar, hastalığın tanı ve teşhisini kolaylaştırmak 
amacı ile vücut sıvılarında biyobelirteçlerin bulunmasına yönelik olmuştur. Bu yönde 
yapılan çalışmalarda, hastalığın seyrinde, beyin omurilik sıvısı (BOS) ve serumda 
immün yanıtı olarak gelişen, miktarlarında farklılık gösteren, çeşitli proteinler 
gözlenmiştir. Bu proteinler seviyeleri ve çeşitleri olarak MS altgruplarında ve kontrol 
gruplarına oran olarak da farklılıklar göstermektedir.  
Bu çalışmada, genel olarak amaç, literatür çalışmaları sonucunda belirlenmiş, MS 
hastalarında seviyeleri değişen proteinlere, MS altgruplarında ve kontrol gruplarında 
bakarak hastalığın seyrini ve alttipini önceden belirlememize yardımcı olacak 
proteinlerin saptanmasıdır. Bu nedenle, İ.Ü. Cerrahpaşa Tıp Fakültesi 
Nöroimmunoloji ve demyelinizan polikliniğinden takipli olan, 20 klinik izole 
sendromlu, 20 yineleyen-düzelen (relapsing-remitting) MS’li, 20 ikincil ilerleyen 
(secondary progressive) MS’li ve 20 birincil ilerleyen (primary progressive) MS’li ve 
20 kontrol grubu olarak yaş ve cinsiyetleri uyumlu farklı nörolojik hastalıklardan 
dolayı lomber ponksiyon yapılması zorunlu olunan hastaların BOS ve serumlarında 
myelin basic protein (MBP), myelin oligodentrosit glikoprotein (MOG), tau proteini, 
glial fibrillar protein (GFAP) ve nörofilament hafif zincirlerine(NF-L) bakılacaktır. 
Proteinlere Western Blot tekniği ile bakılarak, “ImageJ Analysis” programı ile 
seviyelerinde karşılaştırma yapılacaktır. Protein seviyelerini alt gruplarda 
karşılaştırılarak hastalığın seyri ve tanısı açısından biyobelirteç olarak 
değerlendirmesi amaçlanmıştır. 
Yapılan analizler sonucunda, RRMS ve kontrol grubu arasında Tau proteininin 
konsantrasyonu kontrol grubuna oranla RRMS grubunda %53 (p=0.0004), MOG 
proteini 76% (p<0.0001), GFAP proteini 67% (p=0.0034) ve NF – L proteinin %67 
(p=0.0015) oranında arttığı saptanmıştır. Aynı proteinler için CIS ve kontrol grubu 
arasında ise, CIS grubunun Tau proteini konsantrasyonu kontrol grubuna oranla, 
46% (p= 0.0029), MOG proteininde 77% (p<0.0001), GFAP proteininde 57% 
(p=0.0036) ve NF – L proteininde ise %68 (p= 0.0037) oranında arttığı saptanmıştır. 
  
xviii 
MBP proteini için ise istatiksel olarak anlamlı farklar görülmemiştir. Ön 
bulgularımız Tau, MOG, GFAP ve NF – L proteinlerinin hastalığın tanı ve seyrinde 
işlevi olabileceği yönündedir. Çalışmalarımızın devamında örneklem sayısını 
artırarak ve aynı hasta gruplarının serum örneklerinde de bu proteinlerin 
konsantrasyonlarını karşılaştırarak, serum ve BOS arasında korelasyon yapılması 
hedeflenmektedir.
 
1 
1. INTRODUCTION 
1.1 MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating disease of central 
nervous system (CNS) characterized by infiltration of monocytes and lymphocytes to 
the CNS and cause myelin damage in multiple locations and loss of neurological 
function. MS better described as a syndrome rather than a single disease because of 
its complex nature with heterogeneous clinical, pathological and immunological 
phenotype. Chronic nature of the disease decreases the life quality in the patients. 
The clinical heterogeneity of MS has been investigated and evaluated for many 
years, but it is certain that heterogeneity comprises to both the genetic mechanisms 
of the disease and the pathomechanisms involved in lesion formation. In other words, 
MS is a neuroinflammatory and weak neurodegenerative disease of the CNS [1]. 
1.1.1 Symptoms of MS 
Clinical and pathological features of MS are firstly defined in 1868 by Jean-Martin 
Charcot. Since first observations to today, the information about the characteristics of 
pathological mechanisms and the genetics of the disease is still not enough in order 
to understand the whole frame of the disease [2]. Although, more than a century, the 
detailed clinical definition and causes of MS are intensively investigated, still it has 
an unknown pathogenesis. Because of the main target is myelin sheath and its 
producer oligodentroglia, it causes variety of neurological dysfunctions [3]. The 
symptoms of MS start with visual loss or double vision, nystagmus, sensory, and 
motor signs and symptoms. In the progressive forms of the disease, cognitive 
impairments can be seen. Some people have mild cases of multiple sclerosis with 
little or no disability while the others have full-symptomatic MS that confines them 
to a bed or wheelchair. Still others are only diagnosed with multiple sclerosis after 
their death and live their entire lives symptom free. This variability makes it 
extremely difficult to diagnose multiple sclerosis [3-4].  
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1.1.2 Diagnosis of MS 
Diagnosis of MS is extremely difficult depending on the varieties of symptoms. 
There are many reasons complicating the diagnosis: More than fifty symptoms are 
related to MS and degree of the symptoms can develop different for each person. 
Most of these symptoms can be seen in other neurological diseases, also they are 
vague and hard to quantify. There is no single blood test or other radiological 
analyses that confirms the diagnosis of MS. On the other hand, in some cases, history 
and symptoms of the patients are enough to diagnose the disease. But some patients 
may need to be multiple tests and prolonged observation for diagnosis. To 
standardize the diagnosis procedure, there are some criteria which are a combination 
of clinical parameters and radiologic findings with supportive laboratory analyses. 
Before standardization process, diagnosis of MS would be done by using Poser and 
Schumacher criteria, which are also, depend on radiological and clinical findings. 
But in 2001, at the International MS Society meeting, McDonald criteria are 
accepted for the diagnosis of the disease. McDonald’s criteria made usage of 
advances in MRI imaging techniques and facilitate the diagnosis of MS patients who 
present with symptoms suggestive of the disease. In 2005, McDonald’s criteria are 
revised by clarifying what is meant by an “attack”, “positive MRI” etc. Those criteria 
are widely used in all over the world [5]. 
Radiological analyses are depended to the electrophysiological changes caused by 
demyelinating points creating evoked potentials (EP). This can be measured by 
computer tomography (CT) or magnetic resonance imaging (MRI) [5]. These 
techniques are very sensitive to show the white matter demyelination of brain and 
spinal cord [6]. Cellular and humoral immune response plays an important role in the 
formation of demyelination points. Therefore, plasma cell and IgG concentration is 
high in the demyelination centers. Thus, the increase of IgG in the cerebrospinal fluid 
(CSF) can be shown by oligoclonal band analyses (OCB) [7]. 
 
1.2 SUBTYPES OF MS 
MS is classified into different subtypes and its variants, depending on the patterns of 
progressions as well as the intensity and frequency of its generated symptoms. 
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1.2.1 Subtypes of MS 
A) Relapsing – Remitting MS (RRMS) 
RRMS is characterized by the acute attacks (relapses) and following total or partly 
remissions. Additionally, stabile continue of the disease between the attack periods is 
the most common form of the disease. The initial presentation in most patients 
(frequency in all newly diagnosed MS is 85%) is relapsing-remitting MS (RRMS) 
with relapses and remissions due to self-limiting plaques of inflammatory 
demyelination disseminated in time and place in the CNS. Following relapses arises 
in an unpredictable fashion and after each attack level of disability at patient can be 
increased. RRMS show the tendency of turn into secondary progressive MS form in 
the following times [8]. 
 
B) Primary Progressive MS (PPMS) 
In this form of MS, disease progression is continuous from the beginning without 
clear relapses. There can be plateaus (periods of stabilization) time interval. 10–15% 
of all MS patients are in this group and it tends to occur in older aged individuals. 
Usually disease progression continues until death. The female to male ratio is equal 
in this group, unlike other forms where females predominant by about 2–3:1 [8]. 
 
C) Secondary Progressive MS (SPMS) 
This form of MS starts as a RR-MS and approximate 5 or 6 years later steady 
progression occurs with or without relapses. Each attack increases the level of 
disability. Approximately 50% of relapsing-remitting patients progress to the 
secondary progressive form [8] 
 
D) Progressive – Relapsing MS (PRMS) 
This uncommon form (about 5%) is progressive from the onset with superimposed 
relapses (with or without recovery) [8].  
As it is stated above the most common form of MS is RRMS (85%), but in the 
progression of the disease this form turns into one of progressive forms. At the 50% 
of the RRMS cases, it turns into SPMS in 10 years, and at the 90% of the cases it 
turns into SPMS in 25 years. 
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Figure 1.1: MS Subtypes 
 
1.2.2 Clinically Isolated Syndrome (CIS) and Clinical MS Variants  
Besides these 4 main forms of MS, some other variants of the disease are defined 
depending on the clinical onset and the neurological disturbance of the lesions. In a 
significant number of patients who later develop typical MS, the clinical onset starts 
with an acute or subacute episode of neurological disturbance due to monoregional 
involvement of the CNS. This form of presentation is known as clinically isolated 
syndromes (CIS). In some cases of CIS, MRI may reveal polyregional involvement 
of the CNS, in others; the disease will be limited to the corresponding anatomic site, 
remaining monoregional [9]. Although normal brain MRI and CSF IgG index 
indicates the low risk of developing MS in following 5 years but on the other hand, 
positive findings increases this risk 80-90% of the cases [10]. The clinical course of 
CIS also varies;  
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A) Neuromyelitis Optica (Devic’s Syndrome)  
Neuromyelitis Optica is a CIS variant which develops with the acute transverse 
myelitis and synchronic optic neuritis (ON) (inflammation/lesions in the spinal cord 
and optic nerves). In many patients, ON continues with the MS like relapses and 
remittings. Spinal cord lesions can be permanent. Its prognosis is as serious as MS 
and can be finalized with the vision lost. A patient with isolated optic neuritis may 
recover completely, may have recurrences, develop a progressive optic neuropathy, 
may remain symptom-free, or eventually convert to RRMS and SPMS [9-11]. 
 
B) Benign MS (BMS) 
In the 20% of the patients, Benign progression occurs which means that patient 
remains fully functional in all neurological systems 10 years after disease onset. In 
the patients with 5 years asymptomatic, prognosis of BMS chance is considerably 
high [12].  
 
C) Acute Disseminated Encephalomyelitis (ADEM) 
ADEM is a nonvasculitic, inflammatory, demyelinated, immune response originated 
form of MS. It is usually monophasic and frequently seen in 6-8 years old children 
and adolescents. ADEM is separated from MS by this feature of the disease. It 
usually occurs following a viral infection but may appear after one week or month 
vaccination, bacterial or parasitic infection. The prevalence of ADEM in both 
genders is equal and its total prevalence is 0.8/100.000 per year. In the cellular 
mechanism of ADEM, it develops as a humoral response to myelin antigens 
following a vaccination or infection [13]. 
 
D) Marburg Form  
This rare and malign form of MS develops with the progression of the cognitive 
impairments, advanced level of vision loss, dysarthria, dysphagia and respiratory 
problems. It is difficult to differentiate this form from ADEM [14]. 
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1.3 EPIDEMIOLOGY OF MS 
Epidemiology of MS varies between the populations and geographical distributions 
depending on environmental and genetic factors. One observation is that the 
population prevalence of MS increases with distance from the equator. It is estimated 
that there are approximate 34-35/100000 in MS patient in Turkey and it is more 
common in Caucasians (northern Europe) and north part of the world [15]. It is 
postulated that this distribution can be explained in part by both environmental 
factors (e.g. diet and vitamin D abnormalities) and population-specific genetics [16]. 
MS occurs two to three times more in women than men. Although the disease has a 
broad range of age at onset (85% of cases occur between the ages of 14 and 55), 
initial symptoms typically present in early adulthood (between ages 20 and 40). 
Another observation that, incidence of MS is increasing over time [17].  
 
Figure 1.2: World distribution of MS prevalence 
 
 
1.3.1 Classical Family Studies  
Epidemiological studies, indicating familial effect to the disease concludes that first, 
second and third degree of familial relations 5 – 50 times increases the risk of MS 
development. In a family based study Sadovnick AD. et. al. showed that 
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monozygotic siblings (30.3%) have more risk to develop MS than dizygotes (%4.6) 
and siblings (5.1%) [16]. 
 
Table 1.1: MS association in twins and siblings 
[16] 
 
 
 
 
 
 
 
There are several study methods to understand the contribution of environment and 
genetic factors to the disease. In another family based population study, adopted 
children were analyzed to understand the environmental effect to the disease, Ebers 
GC. et. al.’s results indicated that prevalence of MS in adopted children (%0.05) 
were not significantly higher than general population. This result, defined that 
genetic sharing is more important than shared family environment [18]. In another 
study, twin MS patients a sibling with MS patients were analyzed and results 
indicated that, twin MS patients have more recurrence risk (RR) (19%) than general 
population [18, 23]. As it is known half-sibling share 25% of their genetic material 
and full siblings share 50%. The results of the half-sibling study supported the 
adoption data in that genetic sharing and not family environment is critical for the 
familial aggregation of the disease. The data also showed that the half-sibling 
recurrence risk (1·32%) is significantly less than that for full-siblings (3·46%) in the 
same family and is in fact lower than predicted by the halving of genetic sharing in 
oligogenic disorders [19, 20]. 
On the other hand, most investigations about the MS epidemiology indicate that 
migration from a high risk area to the low risk area decreases the possibility of 
developing MS [21]. Numerous familial aggregation studies have shown that 
recurrence risk ratio for MS decreases with the degree of relationship between 
individuals.  Also familial and twin studies showed that, risk of MS development 
increases if there is an MS parent or siblings in family [22]. Compared to the general 
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population, these elevated risks suggest a strong complex inheritance of MS 
susceptibility [22]. 
 
Figure 1.3: Disturbance of recurrence risk among the relatives
[23] 
 
1.3.2 Heritability in MS 
The idea that genetic factors can play a role in MS is first aroused in the second half 
of 19
th
 century with the notification of familial cases. The first genetic association is 
indicated in 1972 with the Human Leukocyte Antigen (HLA) genes. Till 30 years, 
still etiology, environments’ and genes’ contribution to the disease is not certain. MS 
is associated with variation in certain HLA genes on chromosome 6p21, including 
HLA-A, HLA-DRB1, HLA-DQB1, and HLA-DRA on chromosome 6p21.3. Initial 
associations were observed in the HLA class I region of the MHC and later with 
polymorphisms in the HLA class II region. In Northern Europeans, susceptibility has 
been well mapped to an extended HLA class II haplotypes DQA1*0102-
DQB1*0602-DRB1*1501-DRB5*0101. In different studies, genetic susceptibility of 
MS is indicated as 15-20%. As a result, in comparison to total population, primary, 
secondary and other relatives of MS patients show high level of risk. Like all the 
complex diseases, interaction of genes, environment and chance factor, determines 
the susceptibility and progression of MS [19, 30, 31 and 32].  
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1.4 PATHOGENESIS OF MS 
The CNS always considered as an immunologically preserved site with few 
lymphocytes in the case of any active or ongoing infection. However, many studies 
has demonstrated that a small number of T cells traffic through the CNS searching 
for infection or injury and that T cells activated in the periphery can penetrate into 
the blood-brain barrier (BBB) and enter into the CNS. Autoreactive T and B cells are 
normal elements of the immune system. It has been demonstrated that some of these 
autoreactive cells can be stimulated with myelin components in healthy individuals, 
but do not appear to be harmful unless tolerance of the immune system is broken and 
cells activated. Induction of autoimmune responses against myelin components in the 
CNS is thought to be occurred through mechanisms such as molecular mimicry or 
activation and epitope spreading. Once activated, myelin-specific T cells can cross 
the BBB where they proliferate and secrete pro-inflammatory cytokines which in 
turn stimulate microglia, macrophages and astrocytes, and recruit B cells, ultimately 
resulting in damage to myelin, oligodendrocytes and axons [24]. 
 
1.4.1 Pathogenic forms of MS  
Regarding to main characteristics of MS lesions, etiology of MS can be classified 
into four pathologically distinct forms: 
The first etiological cause of MS is that, T- and macrophage cells infiltrate into CNS 
by breaking down the BBB and cause to the myelin sheath damage. But, at the same 
time oligodentrocyte (OLG) cells are alive and fast, thus, total remyelination of 
damaged nerve cells can be observed [34]. 
Another etiological cause is that, activated plasma cells with the T- and macrophage 
cells can be seen in lesions. Loss of OLG cells and migration of progenitor cell is 
also observable in this etiology [34]. In both of those etiologies, main target is 
myelin sheath. 
In The other etiological cause of the disease, there is a vasculite formation in the 
margin of lesion. Infiltration of T cells is less and apoptotic cell death is seen. Axon 
damage and migroglial activation is the main pattern of this etiology. In the last and 
most dangerous etiological cause of the disease, apoptotic cell death and OLG 
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degeneration is observable in the white matter of CNS. Besides, infiltration of T- and 
macrophage cells is also seen. At the last two etiology pattern, the main target is 
OLG cells [34].  
 
 
1.4.2 Immuno – Pathogenesis of MS 
Permeability of BBB to the T cells and demyelinating antibodies can be increased 
with the genetic (super-antigen production) and environmental (viral or bacterial 
infections) factors. The increase of this permeability initially starts with increasement 
in the concentration of adhesion molecules like ICAM-1 (“Intracellular Adhesion 
Molecule-1”), VCAM-1 (“Vascular-Cell Adhesion Molecule-1”) and E-Selectin. 
Then enzymes – like matrix metallo - proteases- initiates the destruction of BBB. 
Activated T cells in the CNS starts the synthesize of pro – inflammatory cytokines 
like IFN-  and TNF- . Those molecules increase the expression of surface molecules 
of lymphocytes and antigen presenting cells (APCs). IFN-  especially stimulates the 
microglia cells to activate as APCs. When a class II MHC carrying APC associates 
with an undifferentiated T cell and MS antigen, it can enter to one of following two 
pathways depending on the co – stimulatory molecule on the surface of the T cell 
[35]. 
 
1.4.2.1 Th1 Pathway 
If the co – stimulatory molecule on the surface of the T cell is CD28 and its ligand 
B7-1 is present there, T cells differentiate into CD4
+
 Th1 cells and synthesize pro-
inflammatory IL-12 and IFN- . While IL-12 stimulates the Th1 pathway, IFN-  
inactivates the Th2 pathway. Concentration of Th1 cells are increased and starts to 
produce IFN-  and TNFα.. Type 1 TNF-α cytokine initiates the death of OLG cells 
and damages to the myelin sheath. This damage occurs with the stimulation of TNF-
α receptors leading to activation of apoptosis and necrosis. When the types 2 TNF-α 
receptors are activated, remyelination process starts. Macrophages which are 
activated by IFN-  cytokines cause to myelin sheath damage by stimulating 
complement response or directly. Also IFN-  causes to OLG damage by stimulating 
cytotoxic CD8
+
 cells. This molecule initiates the Fas gene in the OLG cells and 
when the FasL on the surface of the CD8
+
 interacts with the Fas molecules on the 
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OLG cells, apoptosis of OLG cells occurs [35]. In the course of time, transmission of 
the electrical impuls decreases because of the damage of the myelin sheath on the 
surface of the nerve cells, thus with the environmental factors around the cells axonal 
loss is increased. 
 
1.4.2.2 Th2 Pathway 
If the co – stimulatory molecule on the surface of the T cell is CTLA-4 and its ligand 
B7-2 is present there, T cells differentiate into CD4
+
 Th2 cells and initiate the anti-
inflammatory IL-1, IL-4 and IL-10 cytokines synthesis. While IL-4 and IL-10 
stimulates the Th2 pathway, IL-1 inactivates the Th1 pathway. If extracellular 
infective pathogens present in the environment, they initiates the synthesis of these 
cytokines. Concentration of Th1 cells are increased and start to produce anti-
inflammatory IL-1, IL-4 and IL-13 cytokines. These ILs, activates the B 
lymphocytes and by the expression of antibodies from this cells causes to re-
myelination [35].   
In a healthy body, normally Th1 and Th2 cell and their products are in a balanced 
fashion. When this balance disturbed by the environmental factors, the healthy 
situation turns into the one of MS patterns. Increase in the Th2 by Th1 vaccines, 
sensitivity of B- and T cells to body antigens and do not causing the disease by the 
accidently activation of Th1 cells, supports the idea of presence of autoimmune 
regulating mechanism in the body [38].  
CD4
+
 ve CD8
+
 T- lymphocytes present in the every stages of MS. But usually 
number of CD4
+
 cells is less. In the progression of MS, loss of axon or axonal injury 
is more important than de-myelination. There is a smooth relation between axonal 
loss and the number of CD8
+
 cells. Also, CD8
+
 T cells are more activated in the 
tissue damage of perivascular region. CD4
+
 cells can protect nerve cells by secreting 
notrophin elements. And also in some MS cases, the dominant CD4
+
 cells are not 
Th1 cells, they can be Th2 cells. With this observation and experimental studies, it 
can be concluded that; genetic factors play a bit more key role in deciding to which 
immune system will cause to tissue damage in the nervous system and how CNS will 
respond to this reactions and try to keep re-myelination [39].  
 
 
 
12 
1.4.3 Molecular Pathogenesis of MS 
Studies for the genetics of MS, initially revealed many genes that are related with 
MS, but many of them are eliminated in the following studies due to proof of non-
associated cases. Only 5% of the candidate genes are corrected with the following 
genetic studies. In fact, negative genes are also revealed many useful information as 
well as positive genes. Many strong candidate genes are eliminated by familial 
studies, such as; T cell receptor-α, agonist of interleukin-1 receptor; interferon α, β, γ 
and CCR5, variety of complement and cytokine genes.  
The Apolipoprotein E (APOE) gene codes for a major lipid carrier protein in the 
brain. In previous studies, it is proved that the APOE protein is associated with 
regeneration of axons and myelin after lesions of central and peripheral nervous 
system. Evidence from other motor neurological diseases points out the concept that 
APOE allelic variants may be associated with disease severity. But also, by 
providing a pathway for delivery of self-lipid antigens, APOE can contribute to the 
pathogenesis of MS. Together with the role, this protein may have in neuronal 
remodelling in conjunction with the observations that axonal loss in MS is significant 
and that irreversible clinical disability relates to such axonal loss. APOE is an 
appropriate disease modifying candidate gene for MS. [25, 26, and 27]  
TNF alpha is a cytokine involved in inflammation process and is a member of a 
group of cytokines that stimulate the acute phase reaction. The primary role of TNF 
is in the regulation of immune cells. TNF is also able to induce apoptotic cell death, 
to induce inflammation, and to inhibit tumor formation and viral replication. It is a 
potent immune mediator and pro-inflammatory cytokine. Disease progression in MS 
patients has been correlated with high TNF levels in CSF.. Only one study involving 
50 patients showed any direct effect of TNF alpha on MS outcome. In that study, 
14% of PPMS patients had homozygous point mutations at 308. position, but this 
mutation is not seen in RRMS or control group [28].  
Cytokine (IL) genes are another functional genes in the molecular pathogenesis of 
MS. Development of many autoimmune diseases occurs in the case that   an 
imbalance between the frequency of proinflammatory T helper 1 (Th1),anti-
inflammatory  T helper Type 2 (Th2) T cells, cytokines, and regulatory T cells. In 
MS, it is known that autoreactive T-cells target an antigen in the CNS and initiate an 
inflammatory process resulting to demyelination. Development of autoimmune 
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disease may require not only the presence of autoreactive T cells, but also that these 
autoreactive T cells become activated. As cytokines may drive the inflammatory 
process in an MS plaque, and that acute plaques are associated with acute axonal 
injury and therefore transient neurological dysfunction, it is feasible that cytokine 
polymorphisms may affect prognosis [29]. 
One of the milestone discoveries in MS is the proof of immunoglobulin (Ig) presence 
in the CSF, showing the activity of intrathecal antibody production. The roles of 
intrathecally produced Ig has not been fully understood yet, but results from several 
studies have suggested a role for Ig in the pathogenesis of the MS lesion and perhaps 
severity of disease [30]. 
 
 
Figure 1.4: Immunopathogenesis of MS
[34] 
 
1.5 ANIMAL MODELS OF MS 
Two common animal models for MS have emerged in order to simulate 
demyelination and remyelination in the multiple locations of the brain: 
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1.5.1 Experimental Autoimmune Encephalomyelitis (EAE) Model 
Experimental Autoimmune Encephalomyelitis (EAE), also named experimental 
allergic encephalomyelitis, is an alternative animal model of MS. Animal models of 
human diseases are diseases of non-human species (often rodents and rarely 
primates) which closely resemble their human counterparts of the disease and are be 
studied with a view to better understanding and treating the human form. Actually 
EAE is not MS, nor is it a single disease in a single species, but its different forms 
resemble the various forms and stages of MS very closely in a large number of ways. 
EAE is an acute disease of rodents and also it can be chronic-relapsing, inflammatory 
and demyelinating autoimmune disease. The animals are injected with the whole or 
parts of various myelin antigens. These proteins induce an autoimmune response in 
the animals - that is the animal's immune system initiates an attack on its own myelin 
as a result of exposure to the injection. The animals develop a disease process that 
the symptoms and pathogenesis resembles to MS in humans. Several proteins or 
parts of proteins (antigens) are used to induce EAE including: Myelin Basic Protein 
(MBP), Proteolipid Protein (PLP), and Myelin Oligodendrocyte Glycoprotein 
(MOG).  
Studies on EAE have number of benefits:  
 Because EAE is an animal disease, it enables researchers to study 
demyelination in ways that would not be morally acceptable in studies of MS 
in humans.  
 It allows researchers to test potential treatments for MS for their efficacy 
and safety without putting the lives of people at risk.  
 It allows researchers to experiment with different ways of inducing EAE 
to attempt to find potential causes of MS.  
 Because the generations times of most of the EAE species are short, and 
because they breed very fast, large populations of such animals can be turned 
over in short periods of time. 
Researching EAE has a number of disadvantages:  
 EAE is not a human disease like multiple sclerosis and many significant 
assumptions are made to accept EAE as an animal model for MS.  
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 It is obvious that the animals involved in experiments suffer considerably and 
questions about the ethics of EAE are inescapable [41]. 
 
1.5.2 Cuprizone Neurotoxic Mouse Model for MS 
One of the best characterized demyelinating mouse models is that of cuprizone fed 
mouse model. Several hypotheses have been proposed but it is still unclear why 
cuprizone, a copper chelator molecule, specifically affects OLGs the cell type that 
synthesizes and maintains the myelin sheath of the CNS. The pathogenesis of the 
cuprizone model has been extensively investigated with respect to variations in the 
cuprizone treatment time and dose, the identification of the nerves that demyelinated, 
and the identification of the cellular types that are affected. Diet of 8-week-old 
C57BL/6J mice with 0.2% of cuprizone causes metabolic disturbance and death of 
mature OLGs which leads to a decrease in myelin proteins produced by OLGs such 
as MBP and myelin associated glycoprotein (MAG). This causes extensive 
demyelination of several well-myelinated nerves. The first response to demyelination 
is an activation of microglia/macrophages and reactive astrocytes, which occurs 1–2 
weeks following cuprizone administration. As a response to demyelination and glial 
cell activation, at 3–4 weeks of cuprizone treatment, oligodendrocyte progenitors 
begin to accumulate within the lesion and become mature oligodendrocytes in 2 
weeks, with remyelination occurring over the subsequent 4 weeks if, following 6 
weeks of treatment, the cuprizone is removed from the diet. To date, behavioral 
analysis of cuprizone-treated mice has been poorly studied. [40].  
 
1.6 BIOMARKERS IN MS 
Finding biomarkers for MS is an extensive research area. The main object of 
proteomic studies is to find out an acceptable protein pattern that clinician can 
understand and differentiate the subtype or the course of the disease. As indicated 
above, in the pathogenesis of MS several processes are supposed to sequentially or 
simultaneously contribute to development of the disease. A potential biomarker that 
can be indicative of these processes would help to understand MS diagnostics and 
identification of disease course and subgroups; prediction of onset of disease; 
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treatment selection and improved prognosis of treatment success; and the evaluation 
of novel therapeutics. Though it is difficult that any one marker could function as a 
true indicative, biomarker combinations or patterns could provide insight into the 
mechanism of action of a drug and could suffice for the pre-screening of the disease 
before the onset [42].  
CSF may be better sample in order to show the relevant inflammatory process by its 
localization near to most of inflammatory lesions in the CNS, although this idea 
remains controversial. By the liquid pattern of CSF, it is unlikely that the CSF in the 
lumbar cistern accurately reflects the production of the inflammatory markers in the 
supratentorial region, where most of the inflammation processes relevant to multiple 
sclerosis occurs. In addition, the intraparenchymal extracellular space may not 
necessarily communicate with the free CSF space. However, CSF collection does 
prevent biological degradation of excreted markers by the liver or by renal excretion 
[52]. 
In MS, regarding the complex interactions between immune system and nervous 
system, there are many of candidate proteins that can be thought to as biomarker of 
MS, indicating the characteristics and the subtype of the disease. In this study, five 
proteins have been chosen regarding their role and complex neurological function in 
the nervous system. Those proteins Tau, MBP, MOG, GFAP and NFL are 
investigated through the previous literature findings based on the concentration of 
them in CSFs’ and serums’ of the MS patients. Significant difference of those protein 
levels in subtypes of MS and control samples aroused the idea of candidate 
biomarker in CSF for MS.  
 
1.6.1 Tau Protein in MS 
The microtubule-associated tau proteins in the molecular weight 49–74 kDa play 
important role in stabilization and assembly of microtubules of axons. The 
hyperphosphorylated form of tau is the main protein in the characteristic 
neurofibrillary tangles of Alzheimer’s disease (AD), and increased CSF tau 
concentration is a consistent finding as a biomarker in this disorder. Tau is primarily 
located in neurons, though it can also occur in glial cells as well as it can be released 
to the CSF. Accumulation of tau proteins in neurons as well as in astrocytes and 
oligodendrocytes occurs in various neurodegenerative diseases [44]. 
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In a clinical study, it is showed that concentrations of tau proteins in CSF of RRMS 
patients is higher than in patients with noninflammatory neurological controls 
suggesting that tau could be a good marker in body fluids. In a large study including 
114 MS patients (84 RRMS and 30 progressive form), 79 with inflammatory 
neurological disorders (ND), and 60 with noninflammatory NSs, concluding that 
there was no difference in CSF tau concentrations between MS patients and those 
with inflammatory NDs. Increased CSF tau concentrations (150%) were found only 
in the patients with RRMS, which contrasts with findings in the other study. No 
clinical scores or measures of progression were presented [45, 46].  
In summary, these results suggest that tau protein has a value for further studies in 
serum as well as in CSF in the MS patients, because it is higher in patients with 
RRMS than in non-inflammatory NDs, and it might have a key function in acute 
axonal damage and progression. The association of tau concentrations with AD 
suggests that the protein could be related to cognitive dysfunction in MS as well as in 
AD. Also one another idea suggesting that Tau protein concentration can be vital in 
the progression of disease or changing the form of disease from RR- to PPMS [45, 
46]. 
 
1.6.2 Myelin Basic Protein (MBP) in MS 
Myelin basic protein (MBP) is a protein thought to be important in the myelination 
of nerves in the CNS. The variety of MBP in the CNS is very diverse; with several 
splice variants being expressed and a large number of post-translational 
modifications (PTM) on the protein. 
In many studies, the reactivity of MBP in MS is evaluated with using 7-day 
proliferation assays of whole peripheral blood mononuclear cells. These studies 
showed that a slight increase in T cell responses to human MBP, when compared 
with MS to normal subjects or other ND patients, but the magnitude of the difference 
generally has been less than expected [47]. 
In another study, to understand the binding affinity of immunodominant MBP to 
class I and II type HLA molecules, different T cell types used, by using T cell 
cloning techniques. It is showed that, the MBP peptide bound to purified HLA 
DRB1*1501 molecules with its 84 to 102 amino acids fragments with high affinity. 
This findings also proved by animal models and thus it is understood that 
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autoreactivation of T cells can be induced by the recognition of MBP by specific T 
cells [47].  
 
1.6.3 Myelin Oligodendrocyte Glycoprotein (MOG) in MS 
MOG is another protein in the myelination process of nerves in the CNS. It is coded 
by MOG gene. It is thought that MOG serves as an adhesion molecule to provide the 
structural integrity of myelin sheath and also later it contributes to the development 
of oligodendrocyte. It is a minor type I transmembrane protein which is highly 
expressed in the surface of nerves and oligodendrocyte.  
In many studies, findings related to anti-MOG antibodies in CSF and serums of MS 
patients are variable. Those studies revealed those anti-MOG antibody frequencies 
ranges from 0–80 % in MS patients and 0–60 % in healthy controls. A recent study 
indicating that IgG antibodies directed against native membrane bound, glycosylated 
MOG can be used as serologic markers for early inflammation in MS and it provides 
evidence for a possible prognostic role of anti-MOG antibodies. Furthermore, the 
presence of MOG-specific auto-antibodies associated or not with anti-MBP auto-
antibodies in patients with a first demyelinating event is reported to be highly 
predictive of definite MS [48].  
 
1.6.4 Glial Fibrillary Acidic Protein (GFAP) in MS 
GFAP is an intermediate filament protein that is believed to be expressed only in 
astrocytes and specific for them. But later it is shown that GFAP is also expressed in 
other CNS cell types. Elevated CSF concentrations of GFAP have been found in MS 
patients when compared to other ND control, correlating with disability scales and 
the extent of neurologic deficits and possibly suggesting irreversible tissue 
degeneration. Thus it can be a good biomarker of degeneration in MS. One another 
observation about the GFAP is, in the same study; it is found that, the CSF of PPMS 
and SPMS patients have significantly lower level of this protein in respect to RRMS 
[48]. 
 
1.6.5 Neurofilament Light Chain (NF-L) in MS 
Neurofilaments, are the main cytoskeleton proteins of axons and it consist of three 
components that differ in molecular size: a light chain (NF-L), an intermediate chain 
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(NF-M), and a heavy chain (NF-H). According to many studies, increased 
immunoreactivity of neurofilament has been observed, especially within active MS 
lesions. Neurofilaments and their differential state of phosphorylation in body fluids 
are potential markers for neurodegeneration in MS. Increased concentrations of NF-L 
in CSF have been reported in patients with RR- and PP-MS compared with healthy 
people and patients with inflammatory and non-inflammatory NDs. During relapse, 
concentrations are reported to make a peak in the third week after onset of the 
previous relapse, suggesting a delayed relation with disease activity. NF-L 
concentrations are reported to be independent of age, sex, and disease duration [48]. 
 
1.7 Aim of the Study 
The aim of this study is to investigate the protein biomarkers in different clinical 
subtypes of MS and control groups. To this end, clinical subtypes included 20 
patients from each type of clinically isolated syndrome (CIS), Relapsing remitting 
MS (RRMS), Primary progressive MS (PPMS) and secondary progressive MS 
(SPMS) patients. Additional 20 people were analyzed as disease control group which 
included other neurological but non-inflammatory disorders. Chosen proteins which 
are Tau, MBP, MOG, GFAP and NF-L were analyzed in the CSFs’ of patients and 
control groups by western blotting. Obtained results were analyzed under 
densitometry and Image J analyses programme in order to measure the differences 
semi - quantitatively. Thus, the results were converted to numeric values in order to 
compare with study groups. After CSF experiments, significantly different proteins 
in CSF will be analyzed in serum samples of same patients. Thus, correlation of CSF 
and serum levels of those proteins will be done. Findings from this thesis are 
expected to reveal that, there should be different protein patterns among the MS 
subtypes as well as control samples. Thus, these protein patterns can be candidate 
biomarkers in order to help the diagnosis, differentiation and prognosis of MS. 
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2. MATERIALS AND METHODS 
2.1 Materials and Laboratory Equipments  
 
2.1.1 Used Equipments 
 The laboratory equipment used in this study is listed in Appendix A.  
 
2.1.2. Used Chemicals and Markers  
The chemicals and markers used are given in Appendix B together with their 
suppliers. The compositions and preparation of buffers and solutions are given in 
Appendix C.  
 
2.1.3 Case and Control Group 
Study group is composed of 31 RRMS, 25 CIS, 4 PPMS and 1 SPMS patients who 
came to the Istanbul University, Cerrahpaşa Faculty of Medicine, Neuroimmunology 
and Demyelination Service and diagnosed according to the revised McDonald’s 
criteria (2005). Diagnosis was based on radiologic findings like MRI and brain 
tomography, clinical findings and supportive laboratory analyses. The age of the 
patients ranged from 15 to 55 years. There were 20 females and 10 males.  
Control group composed of 6 patients who came to the Neurology department 
because of other non-inflammatory neurological diseases and apoplexy patients came 
to the Neurosurgery department in Cerrahpaşa faculty of Medicine. Ages and 
genders of the control group were compatible with the patient groups.  
All the samples are coded and numbered before the studies and blind experiments 
were followed. To obtain the other statistical data, patients are questioned for the age 
of onset, age at LP, familial disease history, and used drugs in treatment, job and 
education. The experimental design of this study has been reviewed and approved by 
the Ethics Review Committee of the Cerrahpaşa Medical Faculty of Istanbul 
University. 
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2.2 Collection and Storage of CSF, Serum, Plasma and Blood Samples 
Sample collection of patients and control groups is done at the Neuroimmunology 
and Demyelination Service clinics. Collection of CSF is done by lumbar punction. 
Lumbar punction (LP) is a diagnostic and therapeutic procedure in order to collect 
CSF for further analyses. To remove the CSF, first the patient placed in right or left 
lateral position and his/her neck – chest distance is reduced as possible as, 
approximating a fetal position. LP is performed in the interspaces between the 
lumbar vertebrae, usually at the L4 – L5 level. Before the procedure local anesthetic 
is applied to that region. With a spinal needle, 3cc of CSF is taken in to sterile, dry, 
empty tubes. Than 3cc CSF is separated into 500µl * 6 sterile eppendorph tubes. 
Eppendorph Tubes are kept at -80
0
C until analyses. 
For further analyses, other body fluids were collected from patients and stored. For 
expression profile studies, blood samples were taken into PAXGENE RNA 
(PreAnalytix - Qiagen-BDTM Company) tubes in order to study RNA and stored first 
24 hour in -20
0
C then in -80
0
C freezer. To study on plasma proteins, blood samples 
are collected in P100 Blood Collection System (BDTM) for plasma protein 
preservation. Then tubes are centrifuged at 4000 rpm for 15 minutes, thus plasma is 
separated and tubes were stored at -20
0
C. Serum samples are also taken by using 
mechanical serum separator tubes and after serum was separated, samples were 
aliquated in to sterile eppendorph tubes and stored at -20
0
C. For further genomic 
analyses blood samples were taken into EDTA tubes and stored at -20
0
C. 
 
2.3 Oligoclonal Band Analyses 
Oligoclonal bands (OCB) are the protein bands reflecting the presence of 
immunoglobulin proteins in the samples. OCBs can be seen in both serum and CSF 
samples. Oligoclonal band in CSF but not in serum indicates the CNS production of 
immunoglobulin. Serum can have also immunoglobulin but increased level of IgG in 
CSF rather than serum also indicates the presence of a neurological disorder. The 
presence of OCB in CSF is an important indicator of MS. Protein electrophoresis and 
comassie blue staining method is used to analyze the OCB presence. In this study, 
OCB analyses of CSF samples were done in Istanbul University, Faculty of 
Medicine, microbiology laboratories. 
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2.4 Protein Precipitation from CSF 
Precipitation of proteins from CSF samples was done by following Trichloroacetic 
acid (TCA) protocol. TCA is widely used in biochemistry for the precipitation of 
macromolecules such as proteins, DNA and RNA. Week chlorine bonds in TCA bind 
to positively charged amino acid in proteins and helps to precipitation.  
Frozen CSF samples are dissolved in ice, 1 volume of TCA (100%) stock was added 
to 4 volumes of protein sample in 1,5 ml sterile eppendorph tube and incubated in ice 
for 15 minutes. Then it was centrifuged at 14.000 rpm for 10 minutes and 
supernatant is removed to leave protein pellet intact. Pellet was washed with 200µl 
ice cold acetone and centrifuged again at 14.000 rpm for 5 minutes; this washing step 
is repeated again with 200µl acetone. Than pellet was dried by placing tube in 650C 
for 5 minutes to drive off acetone. Finally, pellet was suspended in 120 or 150µl 
sterile dH2O and mixed by vortexing for 5 minutes. 
 
2.5 Bradford Assay 
Bradford Assay was performed before all the SDS-PAGE and Western Blot 
Analysis. Dr. Marion Bradford firstly described the use of Coomassie Brilliant Blue 
Dye in a colorimetric reagent for the detection and quantification of total protein in 
1976.  In the  acidic environment of  the  reagent,  protein  binds  to  the  coomassie  
dye, which results  in a spectral shift from  the reddish/brown form of the dye 
(absorbance max. at 465 nm) to the blue form of the dye (absorbance max. at 610 
nm). The difference between  the  two  forms  of  the  dye  is  greatest  at  595  nm,  
thus  it  is  the  optimal wavelength  to  measure  the  blue  color  from  the  
coomassie  dye-protein  complex. Besides, the blue color can be measured at any 
wavelength between 575 nm and 615 nm. Bradford protein assay has been associated 
with the presence of certain basic amino acids (primarily arginine, lysine and 
histidine) in the protein. Van der Waals forces and hydrophobic interactions also 
participate in the binding of the dye by protein. The number of coomassie dye 
ligands bound to each protein molecule is approximately proportional to the number 
of positive charges found on the protein. Free amino acids, peptides and low 
molecular weight proteins do not produce color with coomassie dye reagents. The 
assay is performed at room temperature. The measurement was accomplished at 595 
nm by using a 96 well plate. For measurement in a working range 100-1500 µg/ml, 
10 µl protein samples were prepared from protein stocks in a 1:10 ratio, using 
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distilled water as diluent. Bovine serum albumin (BSA) dilutions in a range of 0.125 
mg/ml to 2 mg/ml diluted with distilled water were used as protein standarts. 5 µl of 
BSA  standarts  and  protein  samples were  loaded  in  a  96 well  plate. 200 µl of 
Bradford Reagent was added onto each well and homogenized via pipetting. After 
incubation at room temperature for 2 min, the absorbance values were measured at 
595 nm by Microplate reader 3550-UV (Biorad).   
 
2.6 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) allows 
separation of proteins according to their sizes. %12 Separating gel was prepared with 
4 ml of %30 acrylamide, 2.5 ml of 1,5 M  Tris pH 8.8, 100 µl of %10 SDS, 100 µl of 
%10 APS, 8 µl of TEMED, and 3.3 ml of  dH2O. Separating gel was transferred into 
SDS gel cassette via pipetting. A thin layer of isoprophanol was added onto the gel in 
the casette.  The gel was let at room temperature for 30 min for polymerization. Next, 
the isopropanol in the cassette was discarded with a tissue paper and upper part of the 
gel is completely cleaned from the isopropanol by dH2O. %5 stacking gel was 
prepared via mixing;  670µl of  %30 acrylamide, 500 µl of 0.5 M Tris pH 6.8, 40 µl 
of %10 SDS, 40 µl of %10 APS,  4  µl  of  TEMED,  and  2.7  ml  of  dH2O.  The  
stacking  gel  was  added  onto  the polymerized separating gel  in  the cassette and  
left 45 min at  room  temperature  for  polimerization. 5 µl of ~10 mg/ml protein 
samples was mixed with 4x  loading buffer and denatured at 95°C for 5 min. ~20µl of 
each sample was loaded onto SDS-PAGE  gel. As protein ladder, FERMENTAS 
14.1.3 was used. Measurement of loaded total protein is formulated depending on 
concentration of sample, used sample buffer and volume of buffer with the given 
formula below in figure 2.1. 7µl of protein ladder was loaded onto the SDS-PAGE 
gel. Electrophoresis was accomplished in Tris-glycine running buffer at 90 V, for first 
10 min. and then voltage is increased to 130 V for 90 minutes. The content of the 
running gel is given in the below table 2. 
 
[LP]: Loaded protein concentration 
SV : Sample volume 
MV : Sample – buffer mix volume 
[PTotal] : Total protein concentration 
V: Loaded volume    
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Figure 2.1: Loaded total protein level formula 
 
Table 2.1: Content of Tris– Glycine Runnnig Buffer 
Ingredient     Concentration Amount used in solution 
Tris-HCl   0,125M 3g 
Glycine 0,192M 14,4g 
%10 SDS   %0,1 10ml 
dH2O  1 L 
 
2.7 Western Blotting 
The protein samples separated on SDS-PAGE according to their molecular weight 
and they were transferred to a nitrocellulose membrane and analyzed for presence of 
target proteins. Transfer was performed in a  semi – wet, manual, capillary blotting  
system by means of diffusion of transfer buffer through sponges, napkins and 
Whatmann papers (Transfer  buffer: 3 g of Tris 25mM, 14.4 g Glycine 192mM, 200 
ml of %20 Methanol, 0.05 g of %0.05 SDS, and 1l of dH2O). Transfer is performed 
overnight at 4
o
C.  
 
Figure 2.2: Illustriation of capillary western blot module 
 
                SV 
[LP] =    x [PTotal] x V 
     MV 
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After blotting is completed, Ponceau S method is used in order to analyze whether 
proteins are transferred from gel to the membrane. To do this Ponceau S staining 
solution (0.1% (w/v) Ponceau S in 5% acetic acid) is used. Solution is slowly added 
on to the membrane and it is shaked for at most 10 seconds and than it is cleaned 
with dH2O. If Ponceau S stain is not cleaned with only dH2O then 0.005% NaOH is 
added to the cleaning solution and shakes for 10 seconds.  
After Ponceau S stain completely removed from the nitrocellulose membrane it was 
washed  twice with TTBS buffer at room temperature each for 10 min. [TTBS buffer: 
4.38g of NaCL, 6.05 g of Tris, and 500 ml of dH2O (pH of the buffer was set to pH 
7.4)]. Next, the membrane was incubated at room temperature for at least one hour 
with blocking buffer which included 3% BSA. Then, the membrane was washed with 
TTBS at room temperature each for 10 min (TTBS buffer: 90µl of % 0.05 Tween20 
and 180 ml TBS). Then, the membrane was first incubated with first antibody 
blocking solution at room temperature for one hour. The first antibody blocking 
solution included 5µl of first antibody (200µg/ml) with 10 ml blocking buffer. After 
treating the membrane with first antibody, the membrane was washed again three 
times with TTBS buffer at room temperature each for 10 min. Secondary antibody  
blocking  buffer  was  composed  of    2  µl  of  AP conjugated secondary antibody 
(1:5000), %3 BSA blocking buffer. The membrane was incubated in secondary 
antibody blocking buffer for 1.5 hour at room temperature. Next, the membrane was 
washed  three times with TTBS and once with the NBT/BCIP substrate buffer at  
room  temperature  each  treatment  was  for  10  min. Lastly, the membrane was 
incubated in NCBT/BCIP solution until the protein bands were detectable ( 200µl 
NCBT/BCIP stock solution + 10ml NBT/BCIP buffer; NCBT/BCIP substrate buffer: 
3 g of 0.1 M Tris-HCl pH 9.5, 1.461 g of 0.1 M NaCl2, 2.541 g of 0.05 M 
MgCl2.6H2O, and 250 ml of dH2O). After the substrate incubation was over, 
membrane was washed with dH2O and let it to dry. 
 
2.8 Scanning of Membranes with Densitometry 
Quantitatively analyses of protein bands were achieved by using densitometry 
scanning. Protein bands on the membranes were scanned by using BioRad GSH 800 
densitometry and MagicScan32 V4.5 software. To make the scanning procedure 
Standart, all the scanings are performed in the same settings: 
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Degree of whiteness: 255 
Degree of background color: 200 
Degree of blackness: 1.50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Scanning of the membranes 
 
2.9 Analysis of Samples with ImageJ Anaylsis Programme 
Scanned protein bands on the membranes are analyzed by using ImageJ analysis 
programme to obtain quantitative measurement. Programme measures the density 
and thickness of the protein bands depending on the gathered light. To make the 
analyses procedure standart, all the analyses are performed in the same settings. For 
each protein band, same number of pixels (5000) counted and mean values of the 
measurements are obtained from the programme.   
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Figure 2.4: Analyses of samples with ImageJ 
 
2.10 Statistical Analyses 
Statistical analyses were done by using Student’s t test. Student t test is a statistical 
hypothesis test in which the test statistic has probability distribution. It is applied 
when the population is assumed to be normally distributed but the sample sizes are 
small enough that it relies uncertain estimate of standart deviation (SD) rather than 
on a precisely known value. Analysis programme were used from 
http://www.physics.csbsju.edu/stats/t-test.html online web page. 
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3. RESULTS  
3.1 Sample Characteristics 
52 samples were analyzed including 31 RRMS, 25 CIS, 4 PPMS, 2 SPMS and 12 
control patient. Female to male ratio in study group is almost 2:1. 
 
Gender Number 
Female 19 
Male 43 
Table 3.1: Female to male ratio 
 
3.2 Protein Precipitations and Bradford Assays  
TCA protein precipitation protocol increased the concentration of total protein 
minimum of 10 times. Concentrations of total proteins in samples were measured by 
Bradford assay. Seven standarts protein concentration ranging 0.125 mg/ml to 2 
mg/ml were used.  
 
Figure 3.1: Total protein concentrations in CSF before protein precipitation 
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Figure 3.2: Total protein concentration in CSF after protein precipitation 
 
Precipitation and measurement of total protein was applied to all samples and the 
mean value of CSFs’ total protein among 72 patients was 0.993 and there were no 
significant difference in total protein concentration between different subtypes of MS.  
 
Table 3.2: Total protein concentration of MS subtypes and control 
Group Mean Value 
RRMS(n=31) 1.149 
CIS(n=25) 1.042 
PPMS(n=4) 1.033 
SPMS(n=2) 0.748 
Control(n=12) 1.134 
Total(n=84) 1.040 
 
3.3 SDS-PAGE 
In the SDS – PAGE studies, separation of protein bands were optimized by using 
different concentration of gels and different amount of proteins. Also, albumin and 
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immunoglobulin G (IgG) content of CSF was eliminated by centrifugation and 
ultrafiltration. To separate the protein 2 different concentration of separating gel was 
used: For the proteins Tau (46 kDa) and GFAP (50 kDa), 12% gel, for the other 
proteins NF – L (68 kDa), MOG (28 kDa) and MBP (21.5 kDa) 7.5% gel was used. 
Understanding of localization of interested proteins were achieved by using 
FERMENTAS 14.1.3 protein marker. Loaded total protein values were always 
approximated to ~10mg/ml by using loading formula.  
 
 
Figure 3.3: SDS – PAGE of CSF samples 
 
3.4 Western Blot 
When the transfer of proteins from gel to membrane is completed, Ponceau S staining 
solution was applied to confirm whether transfer was occurred or not. After protein 
bands have seen, destaining solution is applied to continue with western blot. Ponceau 
S staining has showed that transfer conditions for the proteins are optimized as 
overnight at 4
0
C with transfer buffer mentioned in section 2.6. 
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   Figure 3.4: Ponceau S staining       Figure 3.5: Destaining of Ponceau S 
 
Application of antibodies and substrate buffers revealed presence of proteins of 
interests. 
  
Figure 3.6: GFAP and Tau proteins          Figure 3.7: NF–L, MOG, and MBP 
 
3.5 Densitometry scans of membranes 
Scanning’s of all membranes were done in the same settings: 
   
Figure 3.8: Scaning of mebranes 
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3.6 Analysis of protein bands with ImageJ 
Analyses of the protein bands with ImageJ software gives numerical values indicating 
that number 255 is the most whiteness value and 0 is the most blackness value. That 
means, when the density and thickness of bands increases, number given by the 
programme is less. Thus to understand the linearity, reverse value of analyses is 
calculated by using formula (255 – given number). Also to make all analyses in a 
standart procedure, measured value is calculated, as loaded protein value is 10 mg/ml 
by using following formula [(255-given number)/ loaded protein concentration x 10]. 
All the values, for each protein are calculated according to given formula. 
 
 
 
Figure 3.9: Analyses with ImageJ 
 
For example; 
Measured mean value is: 187.768 
Absolute mean value is: 255 – 187.768= 67.232 
Standart mean values is 67.232/10.32*10=65.147 
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Table 3.3: Standart protein concentration values of RRMS patients (n=31) 
Samples Tau GFAP NFL MOG MBP 
MS-ND-1-001/BOS1 48.068 23.844   31.762   
MS-ND-1-002/BOS1 46.952 35.813   33.929   
MS-ND-1-003/BOS1 30.117 14.242   44.008   
MS-ND-1-006/BOS1* 88.205 15.666 34.308 42.443 9.730 
MS-ND-1-007/BOS1 106.934 6.295 29.359 48.005 17.392 
MS-ND-1-008/BOS1 35.327   75.083 35.715 17.898 
MS-ND-1-009/BOS1 68.110 5.766 89.576 160.378 33.841 
MS-ND-1-010/BOS1 118.786 7.648 83.002 77.860 16.372 
MS-ND-1-011/BOS1 32.852 9.034 61.871 43.601 28.261 
MS-ND-1-019/BOS1 47.992 4.539 134.278 46.294   
MS-ND-1-020/BOS1 25.075 11.517 58.171 27.683   
MS-ND-1-024/BOS1 89.188 32.747 16.131     
MS-ND-1-026/BOS1 29.270 4.962 48.084 25.631   
MS-ND-1-027/BOS1 22.808 13.413 32.198 51.316   
MS-ND-1-038/BOS1 79.704 61.436 88.225 34.658 14.497 
MS-ND-1-040/BOS1 55.333 96.481 77.437 55.232 3.951 
MS-ND-1-042/BOS1 45.140 14.390 146.341 65.273 79.697 
MS-ND-1-044/BOS1 41.961 46.192 85.042 9.517 33.082 
MS-ND-1-045/BOS1 16.914 61.972 94.394 47.463 6.536 
MS-ND-1-049/BOS1 74.637 53.820 81.417 53.794   
MS-ND-1-050/BOS1 46.094 68.198 115.487 35.481 0.049 
MS-ND-1-054/BOS1 66.011 39.879 66.532 41.252   
MS-ND-1-055/BOS1 69.038 60.065 162.708 29.650 66.860 
MS-ND-1-056/BOS1 77.906 55.729 138.165 117.075 1.434 
MS-ND-1-060/BOS1 62.980 32.873 59.567 46.541   
MS-ND-1-071/BOS1 84.528 21.904 68.104     
MS-ND-1-072/BOS1 30.027 44.703 85.043 40.108   
MS-ND-1-073/BOS1 61.480 32.856 81.951 50.976   
MS-ND-1-074/BOS1 37.347 22.290 79.110 46.600   
MS-ND-1-075/BOS1 33.631 29.464 72.822 54.992   
MS-ND-1-076/BOS1 35.073 33.827 74.696 56.039   
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Table 3.4: Standart protein concentration values of CIS patients (n=25) 
Samples Tau GFAP NFL MOG MBP 
MS-ND-1-004/BOS1 27.885 38.959   47.403   
MS-ND-1-005/BOS1 27.782 20.439   66.697   
MS-ND-1-012/BOS1 97.939 8.560 45.009 58.488 36.506 
MS-ND-1-013/BOS1 102.232 25.303 59.946 52.851 30.013 
MS-ND-1-014/BOS1 75.542 17.347 73.845 57.197   
MS-ND-1-015/BOS1 67.015 11.922 83.470 41.363   
MS-ND-1-016/BOS1 25.524 2.781 44.036     
MS-ND-1-017/BOS1 30.173 2.920 56.462 33.165   
MS-ND-1-021/BOS1* 23.547 8.361 45.021 26.318   
MS-ND-1-022/BOS1 59.890 25.059   58.808   
MS-ND-1-025/BOS1 31.300 21.557 66.539 39.618   
MS-ND-1-028/BOS1 24.431 7.158 293.613 124.489   
MS-ND-1-031/BOS1 73.674 15.795 56.430 62.634   
MS-ND-1-032/BOS1 50.803 25.189 74.209 53.400   
MS-ND-1-035/BOS1 61.470 15.176 78.749 61.288   
MS-ND-1-036/BOS1 58.821 60.659 31.447 66.874 0.948 
MS-ND-1-037/BOS1 66.333 64.405 112.114 23.507 60.429 
MS-ND-1-039/BOS1 21.120 4.226 104.694 32.456 146.780 
MS-ND-1-041/BOS1 62.738 6.609 43.917 25.645   
MS-ND-1-043/BOS1 37.183   33.954 77.682   
MS-ND-1-047/BOS1 49.324 89.676 156.954 54.195 11.190 
MS-ND-1-062/BOS1 33.371 34.267 67.448 35.608   
MS-ND-1-064/BOS1 23.048 19.191 66.466     
MS-ND-1-065/BOS1 58.602 48.998 147.700 62.562 5.702 
MS-ND-1-067/BOS1 25.397 26.678 67.649     
 
Table 3.5: Standart protein concentration values of PPMS patients (n=4) 
Samples Tau GFAP NFL MOG MBP 
MS-ND-1-030/BOS1 88.915 44.419 61.232 60.863   
MS-ND-1-033/BOS1 88.023 49.069 75.465 63.541   
MS-ND-1-034/BOS1 87.614 70.684 134.846 128.109 32.514 
MS-ND-1-061/BOS1 65.702 62.070 70.209 76.707   
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Table 3.6: Standart protein concentration values of SPMS patients (n=2) 
Samples Tau GFAP NFL MOG MBP 
MS-ND-1-018/BOS1 91.345 42.846 47.697 61.849   
MS-ND-1-023/BOS1 137.977 41.077 160.511 86.432   
 
Table 3.7: Standart protein concentration values of Control samples (n=12)  
Sample Tau GFAP NFL MOG MBP 
MS-ND-1-029/BOS1 20.823 6.632   24.460   
MS-ND-1-046/BOS1 31.758 8.931 20.159 12.305 16.478 
MS-ND-1-048/BOS1 25.715 12.643 28.551 18.339   
MS-ND-1-051/BOS1 29.598 10.276 15.491 10.764   
MS-ND-1-057/BOS1 29.008 9.454 30.124 5.977   
MS-ND-1-058/BOS1 34.137 7.068 14.712 9.067   
MS-ND-1-059/BOS1 23.028 13.018 15.122 10.635   
MS-ND-1-063/BOS1 25.517 8.975 56.567 11.357 69.085 
MS-ND-1-066/BOS1 15.693 1.815 48.727 21.619 73.205 
MS-ND-1-068/BOS1 13.826 2.302 19.872 1.851 3.528 
MS-ND-1-069/BOS1 27.118 14.219 5.124   3.916 
MS-ND-1-070/BOS1 36.051 33.376 36.403 7.558 44.641 
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Figure 3.10: Distribution of proteins in RRMS patients (n=31) 
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Mean values of different proteins in the RRMS groups is shown in figure 3.10. MBP 
could be detected in 14 patients in lower concentrations.  
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Figure 3.11: Distribution of proteins in CIS patients (n=25) 
 
Mean values of different proteins in the CIS groups is shown in figure 3.11. MBP 
could be detected in 7 patients in lower concentrations.  
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Figure 3.12: Distribution of proteins in PPMS patients (n=4) 
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Mean values of different proteins in the PPMS groups is shown in figure 3.12. MBP 
could be detected in only one patient. 
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Figure 3.13: Distribution of proteins in SPMS patients (n=1) 
 
Mean values of different proteins in the SPMS groups is shown in figure 3.13. MBP 
could not be detected.  
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Figure 3.14: Distribution of proteins in control samples (n=12) 
 
Mean values of different proteins in the RRMS groups is shown in figure 3.14. MBP 
could be detected in six samples.  
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Figure 3.15: Mean values of Tau proteins among different groups 
 
Distribution of Tau protein among different groups is shown in figure 3.15. Mean 
value of Tau concentration in RRMS (p=0.004) and CIS (p=0.0029) groups are 
significantly higher than control group. Other groups show a tendency to be higher 
concentration of Tau than control group. But the number of samples are not enough 
for statistical analyses. 
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Figure 3.16: Mean values of GFAP proteins among different groups 
 
40 
 
Distribution of GFAP among different groups is shown in figure 3.16. Mean value of 
GFAP concentration in RRMS (p=0.0034) and CIS (p=0.0036) groups are 
significantly higher than control group. Other groups show a tendency to be higher 
concentration of GFAP than control group. But the number of samples are not enough 
for statistical analyses. 
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Figure 3.17: Mean values of MOG proteins among different groups 
 
Distribution of MOG among different groups is shown in figure 3.17. Mean value of 
MOG concentration in RRMS (p=<0.0001) and CIS (p=<0.0001) groups are 
significantly higher than control group. Other groups show a tendency to be higher 
concentration of MOG than control group. But the number of samples are not enough 
for statistical analyses. 
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Figure 3.18: Mean values of NF – L proteins among different groups 
 
Distribution of NFL protein among different groups is shown in figure 3.18. Mean 
value of NFL concentration in RRMS (p=<0.0001) and CIS (p=<0.0037) groups are 
significantly higher than control group. Other groups show a tendency to be higher 
concentration of NFL than control group. But the number of samples are not enough 
for statistical analyses. 
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Figure 3.19: Mean values of MBP proteins among different groups 
 
42 
Distribution of MBP protein among different groups is shown in figure 3.19. Mean 
value of MBP in CIS group tends to be higher than the other groups as well as control 
group. On the other hand MBP concentration of RRMS has a tendency to be lower 
than control group. 
 
3.7 Student t Test: 
Statistical analyses were done by using student t test because of the less number of 
samples. Probability of hypothesis (p values) was evaluated for RRMS (n=31) and 
CIS (n=25) groups im compare to control sample values (n=12) due to fact that 
sample number of the other groups were not enough for statistical analyses. Meanings 
of pvalues are classified as:  
 p: <0.05 : statistically significant 
 p:<0.01 : statistically very significant 
 p: <0.001 : statistically highly significant 
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4. DISCUSSION AND CONCLUSION 
Tau proteins are microtubule associated proteins that are frequently found in neurons, 
especially in the axons and can be released to CSF. Tau proteins interact with tubulins 
and play important role in the stabilization and assembly of microtubules in the 
axons. Controlling microtubule stability is achieved by two features of Tau: isoforms 
and phosphorylation. By the phosphorylation characteristics of Tau, it can be used as 
a novel biomarker in Alzheimer’s disease. The idea of to be a biomarker in MS for 
Tau protein, arised from the different isoforms of Tau and concentration of it’s in the 
CSF. In a previous study among the 114 MS (84 RRMS and 30 progressive) patients, 
79 inflammatory ONDs and 60 non – inflammatory ONDs controls, it is revealed 
that, for Tau protein even there is no difference between the MS groups, increased 
Tau level was observed (150%) in RRMS groups compared to controls [54]. In our 
study, mean values of CSF level of Tau proteins in RRMS (55.080 CU) (n=31) group 
and CIS group (48.606 CU) (n=25)were compared to the control group (26.023 CU) 
(n=12). It is revealed that, concentration of Tau level is statistically highly significant 
in RRMS group (p=0.0004) and CIS group (p=0.0029) as well as other groups and 
control groups. In PPMS and SPMS, sample numbers are not enough to make a 
statistical analyses in order to compare the level of Tau protein, but the graphics in 
figure 3.15 show that, PPMS and SPMS groups have a tendency of higher 
concentration of Tau than control group. As this results show that, Tau protein can be 
a biomarker of prognosis and diagnosis of MS depending on the its concentration in 
the CSF. Regardind the neurodegenration and Tau protein relation, it may say that 
severity of the disease can be correlated with the Tau protein concentration. 
GFAP is an intermediate filament found in neurons and functional in maintaining the 
mechanical strength of astrocytes, structural integrity of cytoskeleton. It is involved in 
many cellular functioning processses such as functioning of the blood brain barrier. 
Also GFAP is believed to be involved in in the long termupkeep of normal CNS 
myelination. In a previous study, GFAP level of CSFs in PPMS and SPMS show 
significant lower level in respect to RRMS and also elevated CSF level in MS than 
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ONDs. And they correlated this results with the disability scale which means when 
the disability characteristics of the subtypes increases, the level of GFAP, in CSF 
increases [57]. In this study, it is observed that level of GFAP protein in CSF in 
RRMS (32.052 CU) (p=0.0034) and CIS (25.051 CU) (p=0.0036)groups showed 
statistically highly significant level of protein concentration according to the control 
group (10.726 CU). Other groups PPMS (56.561 CU) and SPMS (41.961 CU) have 
also higher level of GFAP concentration but they have not statistically enough 
number of samples to analyse. As previously indicated, GFAP is important in glial 
activation and damage. In regard to blood brain barrier damage and glial activation in 
the pathogenesis of MS, GFAP can play role as a glial and BBB damage biomarker 
and also concentration of GFAP may correlates with the disease disability scale. 
MOG is a glycoprotein that is functional in the myelination of nerves, serves as 
adhesion molecule providing structural integrity and functions in the formation of 
OLG cells. MOG is a major protein thought to be related demyelinating diseases of 
CNS, especially MS. It is a target antigen that leads to autoimmune – mediated 
disease. In a previous study, it is observed that, anti-MOG frequencies varies %0 – 80 
in MS group but higher than ONDs [57]. In this study, it is found that, level of MOG 
in RRMS (50.113 CU) (p<0.0001) and CIS (52.829) (p<0.0001) groups is almost 
same but they show statistically highly significant higher level of protein 
concentration than control group (12.176 CU). Other groups, PPMS (82.305 CU) and 
SPMS (74.141 CU) have also higher level of MOG protein concentration but they 
have not statistically enough number of samples to analyse. Regariding the findings 
in this study and previous findings, it can be said that concentration of MOG in CSF 
may help to understand the OLG damage and give an idea of myelination process in 
MS patients. Thus it may said that MOG can be a good biomarker of OLG damage 
and  level of MOG in CSF may correlates with the disease severity [57]. 
NF – L is an intermediate filament protein, especially found in neurons. It is major 
cytoskeleton protein that is involved in the formation of axons. It may also play role 
in intracellular transport to axons and dendrides. In several studies, it is observed that, 
CSF level of NF – L in RR- and PPMS patients compared with healthy controls is 
increased in a significant level [56, 57]. In this study, concentration of NF – L protein 
in RRMS (79.968 CU) (p<0.0001) and CIS (82.258 CU) (p<0.0037) groups show 
statisticaly highly significant level of increase as protein concentration than control 
group (26.441 CU). By means of protein function, it can be said that, NF – L protein 
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concentration may correlates with the prognosis and disability scale of MS. Thus it 
NF – L protein can be good biomarker showing the axonal damage in the subtypes of 
MS [57]. 
MBP is another main functional protein in the myelination process of nerves in the 
CNS. Various forms of MBP with splice forms and post translational modifications 
are found in CSF and CNS space. In a previous study, it is observed that HLA 
DRB1*1501 allele positive MS patients showed high affinity to bind the MBP and 
their CSF MBP concentration was higher than OND controls [56]. In this study,  14 
patients in RRMS groups, 7 patients in CIS group, one patient in PPMS group not in 
SPMS group and 6 control samples have MBP in their CSF samples. Also results did 
not showed any significant data. Non significant data can be aroused from several 
causes like, higher level of standart deviation caused by less number of  samples, non 
– suitable antigen – antibody interaction caused by several isoforms of MBP protein 
in CSF. There may be another variant of MBP which is more abundant in CSF. 
Addition to this MBP isoform, other MBP forms should be studied and their 
differences should be understanded. 
To sum up, this is the first study evaluating, five different, novel, candidate 
biomarkers in four main subtypes of MS patients and control samples. Moreover, 
quantitative approaches with those proteins by using western blot technique is another 
improvement that we applied for evaluating the level of proteins in that subtypes. 
Another feature of this study is, first clinical isolated syndrome study, comparing the 
level of same proteins with the MS subtypes. At the end, four of five proteins showed 
significant findings about their level in different groups. Even statistical findings are 
showing the significant results, sample numbers of groups are still not enough. 
Especially in prograssive forms (PPMS and SPMS) sample numbers should be 
increased as well as in control group. But on the other hand, sample collection is 
continuing and number of samples will be increased.  
At the another part of the project, serum samples of the same patients and control 
samples will be analyzed and a quantitative comparison will be done between the 
serum and CSF level of those proteins. Also serum and CSF level of those protein 
comparison will also be the first study evaluating different proteins, in different 
groups and in different sample types. Actually this study is a preliminary study of 
future projects, including biomarker investigation study by using proteome researchs 
and methylome analyses of MS patients and subgroups. Also, these data can be 
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integrated into another project: Mathematical and animal modeling of MS to 
understand the pathological and immune mechanisms in MS.  
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APPENDIX A  
 
LABORATORY EQUIPMENT  
  
Balances Schimadzu 
Precisa   
Eppendorf 
Centrifuges       Allegra 25R Centrifuge Beckman 
Coulter               
Sigma 
Minicentrifuge   Beckman coulter   
Electrophoresis Equipments       Stratagene 
Gel Documentation System       BIO-RAD 
Mini-Vertical Gel System         BioWorld 
Orbital Shaker           Forma 
Thermomixer    Eppendorf 
Microplate Reader            Biorad 
pH meter             Mettler Toledo MP220 
Vortex                     Kermanlar 
Pipettes Thermo Finnpipette 1000 μl 
10 µL, 200 μl   
Laminar Air Flow Cabin                   Thermo Scientific 
Fridge and Freezers (+4°C, -20°C, -
80°C)    
Heraeus  Sepatech,  Bosch, Sanyo, 
Arcelik 
Water Distillation System          Millipore 
Autoclave  
Ice Machine    Arçelik 
Power Supply Thermo Scientific 
Densitometry BioRad 
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APPENDIX B  
 
CHEMICALS  
Acrylamide Merck 
Antibodies for Western Blot                 Santa Cruz Biotechnology: 
sc-32274 Tau (46) 
sc-33673 GFAP (2E1) 
sc-25652 NF-L (H-70) 
sc-66968 MOG (H-72) 
sc-25665 MBP (FL-304) 
B-Mercaptoethanol         Sigma 
Bis-Acrylamide Merck 
Bromophenol Blue         Sigma 
Bovine Serum Albumine Sigma Aldrich 
DTT (Dithiothreitol) Fermentas 
Ethanol    Merck  
Riedel-de Haën 
Glacial Acetic Acid     Merck 
Glycerol Sigma   
Glycine Merck 
HCl Merck 
Isopropanol Fluka 
KCl Carlo Erba        
MgCl2 Merck 
Methanol Fluka 
NaCl Carlo Erba 
NaOH Riedel-de Haën 
Nitro blue tetrazolium 5-Bromo 4-
chloro-3- indosyl phosphate (NBT/BCIP) 
Roche 
Nitrocellulose Membrabe Santa Cruz:  
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sc-3724 0.45 µm Pore  
sc-3718 0.22 µm Pore 
Ponceau S Riedel-de Haën 
Sodium dodecyl sulfate (SDS)    Merck 
TEMED Merck   
Tris Base   Merck  
Sigma 
Tween 20 Merck   
2-mercapto-ethanol   Merck 
 
 
MARKERS 
FERMENTAS 1.4.1 Protein Marker 
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APPENDIX C 
 
SOLUTIONS and BUFFERS 
 
Protein Precipitation Buffers 
Trichloro Acetic Acid (TCA) Solution: 
TCA solution dilution of final concentration 2.2g/ml was prepared with dH2Oand 
powder TCA stock.  
 
SDS-PAGE Buffers 
SDS Sample Buffer (4X) 
       Final Concentarion 
Tris-HCl, 0.5M, pH:6.8    0.25 M 
SDS       8% 
2-mercaptoethanol (10mM)    10% 
Glycerol      30% 
Bromophenol Blue     0.002% 
 
SDS Running Buffer (1X) 
      Final Concentration 
Tris-HCl 0.5M     0.025 M 
Glycine      0.192 M 
SDS       0.1% 
 
Comassie Brilliant Blue (CBB) Stain Dye 
      Final Concentration 
CBB       0.1 % 
MeOH       50 % 
Acetic Acid      10% 
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CBB Destain Dye 
      Final Concentration 
MeOH       10% 
Acetic Acid      10% 
Seperating Gel (2V) 
       7.5 %   12% 
dH2O        4.85ml 3.3 ml 
Acrylamide – Bis- (30% - 0.8%)   2.45 ml 4 ml 
1.5M Tris HCl, pH:6.8    2.5 ml  2.5 ml 
10% SDS      0.1 ml  0.1 ml 
10% APS (100 mg/ml)    0.1 ml  0.1 ml 
TEMED      8 µl  8µl 
 
Stacking Gel (2V)            4% 
dH2O        2.7 ml 
Acrylamide – Bis- (30% - 0.8%)    0.67 ml 
1.5M Tris HCl, pH:6.8     0.5 ml 
10% SDS       0.04 ml 
10% APS (100 mg/ml)     0.04 ml 
TEMED       4µl 
 
Bradford Standarts 
Standart 0:  30 ml dH2O 
Standart 1:  0.125 mg/ml BSA + 30 ml dH2O 
Standart 2:  0.25 mg/ml BSA + 30 ml dH2O 
Standart 3:  0.5 mg/ml BSA + 30 ml dH2O 
Standart 4:  0.75 mg/ml BSA + 30 ml dH2O 
Standart 5:  1 mg/ml BSA + 30 ml dH2O 
Standart 6:  1.5 mg/ml BSA + 30 ml dH2O 
Standart 7:  2 mg/ml BSA + 30 ml dH2O 
 
Western Blot Buffers 
 
Towbin Transfer Buffer 
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      Final Concentration 
Tris Base   3g   0.025 M 
Glycine    14.4g   0.192 M 
Methanol   200 ml   20% 
dH2O    added to 1 lt. 
TBS 
      Final Concentration 
NaCl    8.76g   0.15 M 
Tris    12.1g   0.01 M  
dH2O    added to 1 lt 
pH is adjusted to 8.0 
 
TTBS Wash Buffer (0.1%v/v) 
TBS    990 ml  
Tween 20   10 ml 
 
Blocking Buffer 
      Final Concentration 
BSA    3g   3% 
dH2O    added to 100 ml 
 
NBT/BCIP Substrate Buffer 
      Final Concentration 
Tris – HCl, pH: 9.5   3g   0.1M 
NaCl2     1.461g   0.1M 
MgCl2. 6H2O   2.541   0.1M  
dH2O    added to 250 ml 
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